Clinigen
Clinigen Group plc, headquartered in the United Kingdom, is a leading global pharmaceutical and services company specialising in the provision of access to medicines. Founded in 2010, Clinigen has rapidly established itself in the healthcare industry, focusing on unlicensed and niche products, clinical trial services, and the management of complex supply chains. With a strong presence in Europe, North America, and Asia, Clinigen offers unique solutions that bridge the gap between pharmaceutical companies and patients. Their core services include the provision of clinical trial supplies and the management of access programmes, ensuring that patients receive critical treatments when they need them most. Clinigen's commitment to patient access and innovative solutions has positioned it as a trusted partner in the global healthcare landscape, achieving significant milestones in expanding its product offerings and market reach.
DitchCarbon Score
How does Clinigen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Clinigen's score of 47 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Clinigen's reported carbon emissions
Clinigen, headquartered in Great Britain, has set ambitious climate commitments aimed at significantly reducing its carbon emissions. Although specific emissions data for the most recent year is not available, Clinigen has established a comprehensive strategy to address its greenhouse gas (GHG) emissions across various scopes. The company aims for a 42% reduction in absolute Scope 1 and Scope 2 GHG emissions by 2030, starting from 2022. Additionally, Clinigen is targeting a similar 42% reduction in Scope 3 emissions, specifically from air and road freight, within the same timeframe. Looking further ahead, Clinigen has committed to a substantial 90% reduction in absolute GHG emissions across all scopes by 2040. This long-term goal aligns with their Net Zero ambition for 2040, which is in line with the targets set by Triton, their parent company. Clinigen's commitment to sustainability is further reinforced by their participation in the Science Based Targets initiative (SBTi), where they have committed to achieving Net Zero emissions by 2050. This comprehensive approach underscores Clinigen's dedication to mitigating climate change and enhancing its environmental performance within the pharmaceuticals, biotechnology, and life sciences sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Clinigen is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
